Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
national blog main
boston blog main
boston top stories
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
abbvie
biotech
drugs
fda
new york
parkinson's disease
pfizer
4d molecular therapeutics
acne
acorda therapeutics
agenus
akcea therapeutics
ampyra
anylam pharmaceuticals
apokyn
apomorphine
astrazeneca
auris health
avexis
bayer
bial
biomx
bladder cancer
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
broad institute of mit and harvard
cancer
cancer immunotherapy
cancer vaccines
What
disease
4
×
fda
4
×
approved
drug
patients
gets
nod
parkinson’s
treatment
acorda
add
ago
akcea
alnylam
amyloidosis
attr
available
battle
bio
called
carbidopa
combination
companies
control
cope
daily
debilitating
digital
epidemic
episodes
experience
fatty
frenzied
friday
genetic
growing
help
known
late
led
Language
unset
Current search:
xconomy.com
×
disease
×
fda
×
@xconomy.com
4 years ago
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms